Related Experiment Videos
Endocrinological disturbances in chronic obstructive pulmonary disease
1Dept of Respiratory Medicine, University Hospital Maastricht, The Netherlands. E.Creutzberg@PUL.Unimaas.NL
The European Respiratory Journal. Supplement
|November 19, 2003
Summary
Endocrinological disturbances in chronic obstructive pulmonary disease (COPD) are reviewed, focusing on growth hormone/insulin-like growth factor I (IGF-I), thyroid, and anabolic hormones. Further research is needed to clarify their roles and guide potential treatments for COPD patients.
Area of Science:
- Endocrinology
- Pulmonology
- Metabolic Research
Background:
- Chronic obstructive pulmonary disease (COPD) is associated with complex physiological changes.
- Endocrinological disturbances may contribute to the pathophysiology and progression of COPD.
- Hormonal imbalances, including those related to growth hormone, thyroid, and anabolic steroids, warrant further investigation in COPD.
Purpose of the Study:
- To review the current literature on endocrinological disturbances in COPD.
- To examine the roles of growth hormone/insulin-like growth factor I (IGF-I), thyroid hormones, and anabolic steroids in COPD.
- To identify gaps in knowledge and areas for future research regarding hormonal dysregulation in COPD.
Main Methods:
- Comprehensive literature review of studies investigating endocrinological parameters in COPD patients.
- Analysis of findings related to growth hormone, IGF-I, thyroid function, and anabolic steroid levels (e.g., testosterone).
- Evaluation of existing evidence on the functional consequences and potential therapeutic interventions for hormonal disturbances in COPD.
Main Results:
- Circulating growth hormone and IGF-I concentrations in COPD show conflicting results, with potential links to hypoxemia; growth hormone supplementation has shown no clear functional benefits to date.
- Thyroid dysfunction is not consistently observed in COPD, except possibly in severe hypoxemia cases, requiring further study.
- Hypogonadism (low testosterone) is common in male COPD patients, potentially linked to glucocorticosteroids and inflammation, but its functional impact and the efficacy of testosterone replacement require more evidence.
Conclusions:
- The precise roles and clinical significance of growth hormone/IGF-I, thyroid hormones, and anabolic steroids in COPD remain incompletely understood.
- Current evidence does not support routine hormonal supplementation (e.g., growth hormone, testosterone) in COPD without further robust clinical trials.
- Additional research is crucial to elucidate the mechanisms, consequences, and optimal management strategies for endocrinological disturbances in COPD patients.